Hydroxycarbamide treatment in sickle cell disease: estimates of possible leukaemia risk and of hospitalization survival benefit

Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group

(2014) D. A. Eichenauer et al.   BLOOD

Therapy-Related Acute Myelogenous Leukemia in a Hydroxyurea-Treated Patient With Sickle Cell Anemia

(2013) James G. Taylor et al.   ANNALS OF INTERNAL MEDICINE

Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008

(2013) L. M. Morton et al.   BLOOD

The effect of hydroxcarbamide therapy on survival of children with sickle cell disease

(2013) Clarisse Lopes de Castro Lobo et al.   BRITISH JOURNAL OF HAEMATOLOGY

Severe Painful Vaso-Occlusive Crises and Mortality in a Contemporary Adult Sickle Cell Anemia Cohort Study

(2013) Deepika S. Darbari et al.   PLoS One

Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?

(2011) Patrick T McGann et al.   CURRENT OPINION IN HEMATOLOGY

The rationale for using hydroxycarbamide in the treatment of sickle cell disease

(2011) D. C. Rees   HAEMATOLOGICA

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)

(2011) Winfred C Wang et al.   LANCET

Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease

(2010) James R. Stallworth et al.   AMERICAN JOURNAL OF HEMATOLOGY

Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease

(2010) Carlton Haywood et al.   AMERICAN JOURNAL OF HEMATOLOGY

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)

(2009) E. Voskaridou et al.   BLOOD